SEC Tracker
Get the app

Anavex Life Sciences AVXL

Anavex receives FDA go-ahead for clinical study

Form
8-K
Filed
Importance
Routine
  1. FDA allows clinical study for blarcamesine in Fragile X syndrome
  2. Exhibit 99.1 includes the press release

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Anavex Life Sciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2836) and public float $300M to $2B, nearest public float first, as each company reports it on its annual report cover.

  1. ImmunityBio IBRX public float $690M, Jun 30, 2025
  2. LENZ Therapeutics LENZ public float $690M, Jun 30, 2025
  3. Vir Biotechnology VIR public float $689M, Jun 30, 2025
  4. Relay Therapeutics RLAY public float $586M, Jun 30, 2025
  5. Ginkgo Bioworks Holdings DNA public float $553M, Jun 28, 2025